These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 16255678)

  • 1. Protease inhibitors as potential disease-modifying therapeutics for Alzheimer's disease.
    Beher D; Graham SL
    Expert Opin Investig Drugs; 2005 Nov; 14(11):1385-409. PubMed ID: 16255678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity.
    Barten DM; Meredith JE; Zaczek R; Houston JG; Albright CF
    Drugs R D; 2006; 7(2):87-97. PubMed ID: 16542055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gamma-secretase as a therapeutic target for the treatment of Alzheimer's disease.
    Churcher I; Beher D
    Curr Pharm Des; 2005; 11(26):3363-82. PubMed ID: 16250842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease.
    Pollack SJ; Lewis H
    Curr Opin Investig Drugs; 2005 Jan; 6(1):35-47. PubMed ID: 15675602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. γ-Secretase inhibitors and modulators for Alzheimer's disease.
    Wolfe MS
    J Neurochem; 2012 Jan; 120 Suppl 1(Suppl 1):89-98. PubMed ID: 22122056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gamma-secretase inhibition.
    Beher D; Shearman MS
    Biochem Soc Trans; 2002 Aug; 30(4):534-7. PubMed ID: 12196131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The search for gamma-secretase and development of inhibitors.
    Tsai JY; Wolfe MS; Xia W
    Curr Med Chem; 2002 Jun; 9(11):1087-106. PubMed ID: 12052174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease-modifying therapies in Alzheimer's disease: how far have we come?
    Hüll M; Berger M; Heneka M
    Drugs; 2006; 66(16):2075-93. PubMed ID: 17112302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. gamma-Secretase as a target for drug intervention in Alzheimer's disease.
    Harrison T; Churcher I; Beher D
    Curr Opin Drug Discov Devel; 2004 Sep; 7(5):709-19. PubMed ID: 15503873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity.
    Shearman MS; Beher D; Clarke EE; Lewis HD; Harrison T; Hunt P; Nadin A; Smith AL; Stevenson G; Castro JL
    Biochemistry; 2000 Aug; 39(30):8698-704. PubMed ID: 10913280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid metabolism and secretases in Alzheimer's disease.
    Xia W
    Curr Neurol Neurosci Rep; 2001 Sep; 1(5):422-7. PubMed ID: 11898552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE.
    Vassar R; Bennett BD; Babu-Khan S; Kahn S; Mendiaz EA; Denis P; Teplow DB; Ross S; Amarante P; Loeloff R; Luo Y; Fisher S; Fuller J; Edenson S; Lile J; Jarosinski MA; Biere AL; Curran E; Burgess T; Louis JC; Collins F; Treanor J; Rogers G; Citron M
    Science; 1999 Oct; 286(5440):735-41. PubMed ID: 10531052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective amyloid-beta lowering agents.
    Wolfe MS
    BMC Neurosci; 2008 Dec; 9 Suppl 2(Suppl 2):S4. PubMed ID: 19090992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gamma-secretase: a catalyst of Alzheimer disease and signal transduction.
    Li YM
    Mol Interv; 2001 Oct; 1(4):198-207. PubMed ID: 14993342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular rationale for the pharmacological treatment of Alzheimer's disease.
    Zimmermann M; Gardoni F; Di Luca M
    Drugs Aging; 2005; 22 Suppl 1():27-37. PubMed ID: 16506440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secretase as a target for Alzheimer's disease.
    Wolfe MS
    Curr Top Med Chem; 2002 Apr; 2(4):371-83. PubMed ID: 11966461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secretases as therapeutic targets for the treatment of Alzheimer's disease.
    Dominguez DI; De Strooper B; Annaert W
    Amyloid; 2001 Jun; 8(2):124-42. PubMed ID: 11409035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The structural evolution of β-secretase inhibitors: a focus on the development of small-molecule inhibitors.
    Butini S; Brogi S; Novellino E; Campiani G; Ghosh AK; Brindisi M; Gemma S
    Curr Top Med Chem; 2013; 13(15):1787-807. PubMed ID: 23931442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BACE1: the beta-secretase enzyme in Alzheimer's disease.
    Vassar R
    J Mol Neurosci; 2004; 23(1-2):105-14. PubMed ID: 15126696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics.
    Roberds SL; Anderson J; Basi G; Bienkowski MJ; Branstetter DG; Chen KS; Freedman SB; Frigon NL; Games D; Hu K; Johnson-Wood K; Kappenman KE; Kawabe TT; Kola I; Kuehn R; Lee M; Liu W; Motter R; Nichols NF; Power M; Robertson DW; Schenk D; Schoor M; Shopp GM; Shuck ME; Sinha S; Svensson KA; Tatsuno G; Tintrup H; Wijsman J; Wright S; McConlogue L
    Hum Mol Genet; 2001 Jun; 10(12):1317-24. PubMed ID: 11406613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.